What is the current valuation of the Basal Insulin (Long Acting Insulin) Market as of 2024?

The market valuation was 27.02 USD Billion in 2024. Read More

What is the projected market size for the Basal Insulin market by 2035?

The projected valuation for the market is 41.2 USD Billion by 2035. Read More

What is the expected CAGR for the Basal Insulin market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 3.91%. Read More

Which companies are the key players in the Basal Insulin market?

Key players include Sanofi, Novo Nordisk, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck, AstraZeneca, Pfizer, and Baxter. Read More

What are the leading products in the Basal Insulin market by type?

Leading products include Lantus, Levemir, Tresiba, Basaglar, and Toujeo, with Lantus valued at 8.5 to 12.5 USD Billion. Read More

How does the delivery method segment perform in the Basal Insulin market?

The delivery method segment includes Pen, Syringe, Pump, and Pre-filled Device, with Pen valued at 8.1 to 12.5 USD Billion. Read More

What is the market performance for different patient types in the Basal Insulin market?

The market for Type 1 Diabetes is valued at 5.0 to 8.0 USD Billion, while Type 2 Diabetes is valued at 15.0 to 24.0 USD Billion. Read More

What dosage forms are available in the Basal Insulin market?

The market includes Solution and Suspension, with Solution valued at 15.0 to 23.0 USD Billion. Read More

How does the market for Basal Insulin compare between 2024 and 2035?

The market is expected to grow from 27.02 USD Billion in 2024 to 41.2 USD Billion by 2035. Read More

What trends are influencing the growth of the Basal Insulin market?

Trends include increasing diabetes prevalence and advancements in insulin delivery technologies, contributing to market growth. Read More

Basal Insulin (Long Acting Insulin) Market

ID: MRFR/HC/40642-HCR

200 Pages

Rahul Gotadki

Last Updated: April 15, 2026

Basal Insulin (Long Acting Insulin) Market Research Report By Type (Lantus, Levemir, Tresiba, Basaglar, Toujeo), By Delivery Method (Pen, Syringe, Pump, Pre-filled Device), By Patient Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), By Dosage Form (Solution, Suspension) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 Lantus | |
  2. 4.1.2 Levemir | |
  3. 4.1.3 Tresiba | |
  4. 4.1.4 Basaglar | |
  5. 4.1.5 Toujeo |
2. 4.2 Healthcare, BY Delivery Method (USD Billion) | |
  1. 4.2.1 Pen | |
  2. 4.2.2 Syringe | |
  3. 4.2.3 Pump | |
  4. 4.2.4 Pre-filled Device |
3. 4.3 Healthcare, BY Patient Type (USD Billion) | |
  1. 4.3.1 Type 1 Diabetes | |
  2. 4.3.2 Type 2 Diabetes | |
  3. 4.3.3 Gestational Diabetes |
4. 4.4 Healthcare, BY Dosage Form (USD Billion) | |
  1. 4.4.1 Solution | |
  2. 4.4.2 Suspension |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Sanofi (FR) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Novo Nordisk (DK) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bristol-Myers Squibb (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Lilly (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Merck (DE) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 AstraZeneca (GB) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Pfizer (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Baxter (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY DELIVERY METHOD |
8. 6.5 US MARKET ANALYSIS BY PATIENT TYPE |
9. 6.6 US MARKET ANALYSIS BY DOSAGE FORM |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY DELIVERY METHOD |
12. 6.9 CANADA MARKET ANALYSIS BY PATIENT TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY DOSAGE FORM |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY DELIVERY METHOD |
17. 6.14 GERMANY MARKET ANALYSIS BY PATIENT TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY DOSAGE FORM |
19. 6.16 UK MARKET ANALYSIS BY TYPE |
20. 6.17 UK MARKET ANALYSIS BY DELIVERY METHOD |
21. 6.18 UK MARKET ANALYSIS BY PATIENT TYPE |
22. 6.19 UK MARKET ANALYSIS BY DOSAGE FORM |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY DELIVERY METHOD |
25. 6.22 FRANCE MARKET ANALYSIS BY PATIENT TYPE |
26. 6.23 FRANCE MARKET ANALYSIS BY DOSAGE FORM |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD |
29. 6.26 RUSSIA MARKET ANALYSIS BY PATIENT TYPE |
30. 6.27 RUSSIA MARKET ANALYSIS BY DOSAGE FORM |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY DELIVERY METHOD |
33. 6.30 ITALY MARKET ANALYSIS BY PATIENT TYPE |
34. 6.31 ITALY MARKET ANALYSIS BY DOSAGE FORM |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY DELIVERY METHOD |
37. 6.34 SPAIN MARKET ANALYSIS BY PATIENT TYPE |
38. 6.35 SPAIN MARKET ANALYSIS BY DOSAGE FORM |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY DELIVERY METHOD |
46. 6.43 CHINA MARKET ANALYSIS BY PATIENT TYPE |
47. 6.44 CHINA MARKET ANALYSIS BY DOSAGE FORM |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY DELIVERY METHOD |
50. 6.47 INDIA MARKET ANALYSIS BY PATIENT TYPE |
51. 6.48 INDIA MARKET ANALYSIS BY DOSAGE FORM |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY DELIVERY METHOD |
54. 6.51 JAPAN MARKET ANALYSIS BY PATIENT TYPE |
55. 6.52 JAPAN MARKET ANALYSIS BY DOSAGE FORM |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD |
62. 6.59 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY DELIVERY METHOD |
66. 6.63 THAILAND MARKET ANALYSIS BY PATIENT TYPE |
67. 6.64 THAILAND MARKET ANALYSIS BY DOSAGE FORM |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD |
70. 6.67 INDONESIA MARKET ANALYSIS BY PATIENT TYPE |
71. 6.68 INDONESIA MARKET ANALYSIS BY DOSAGE FORM |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD |
74. 6.71 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD |
79. 6.76 BRAZIL MARKET ANALYSIS BY PATIENT TYPE |
80. 6.77 BRAZIL MARKET ANALYSIS BY DOSAGE FORM |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY DELIVERY METHOD |
83. 6.80 MEXICO MARKET ANALYSIS BY PATIENT TYPE |
84. 6.81 MEXICO MARKET ANALYSIS BY DOSAGE FORM |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD |
87. 6.84 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD |
104. 6.101 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DELIVERY METHOD, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY PATIENT TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY DOSAGE FORM, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Basal Insulin (Long Acting Insulin) Market Segmentation

Basal Insulin (Long Acting Insulin) Market By Type (USD Billion, 2025-2035)

Lantus
Levemir
Tresiba
Basaglar
Toujeo

Basal Insulin (Long Acting Insulin) Market By Delivery Method (USD Billion, 2025-2035)

Pen
Syringe
Pump
Pre-filled Device

Basal Insulin (Long Acting Insulin) Market By Patient Type (USD Billion, 2025-2035)

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Basal Insulin (Long Acting Insulin) Market By Dosage Form (USD Billion, 2025-2035)

Solution
Suspension

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”